Arabic Arabic English English French French German German
dark

MAX BioPharma Announces Publication of Proof of Principle Regarding its Oxysterol Lead Drug Candidate, Oxy210 that Inhibits Fatty Liver and Fibrosis in a Humanized Mouse Model

Max BioPharma , Inc. ( www.maxbiopharma.com ) recently published an article that reported the efficacy of its anti-fibrotic and anti-inflammatory oxysterol lead compound, Oxy210, in the peer-reviewed journal,  Endocrinology, Diabetes & Metabolism .  Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Industry Veteran Rusty Williams Leads Startup to $50 Million Series A

Next Post

Successful demonstration of BioDrone® platform-based drug delivery and confirmed restoration of the myogenic potential of Prokr1-deficient C2C12 myoblasts

Related Posts
Total
0
Share